| scholarly article | Q13442814 |
| P50 | author | Suresh Senan | Q37830477 |
| Joachim Widder | Q41085060 | ||
| Ritsuko Komaki | Q64585410 | ||
| Harry J M Groen | Q86505093 | ||
| Mark F Munsell | Q90326364 | ||
| P2093 | author name string | Lei Feng | |
| Donald A Berry | |||
| Jack A Roth | |||
| Egbert F Smit | |||
| Reza J Mehran | |||
| Joe Y Chang | |||
| Alexander V Louie | |||
| Anne-Marie Dingemans | |||
| Ben E E M van den Borne | |||
| Ben J Slotman | |||
| Coen Hurkmans | |||
| Cornelis J A Haasbeek | |||
| Erik van Werkhoven | |||
| John J Kresl | |||
| Katrien De Jaeger | |||
| Larry S Carpenter | |||
| Marinus A Paul | |||
| Omar Dawood | |||
| Peter Balter | |||
| Stephen E McRae | |||
| P2860 | cites work | Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly | Q30640824 |
| Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors | Q31145126 | ||
| Stereotactic body radiation therapy for inoperable early stage lung cancer | Q34010065 | ||
| Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group | Q34721402 | ||
| Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer | Q36241457 | ||
| Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer | Q36327908 | ||
| Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy | Q37330615 | ||
| Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis | Q37592621 | ||
| Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? | Q37773607 | ||
| Mediastinal staging of lung cancer: novel concepts | Q38007233 | ||
| Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database | Q40051115 | ||
| Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. | Q40349654 | ||
| Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. | Q44017103 | ||
| Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis | Q44592987 | ||
| Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery | Q45395354 | ||
| Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality | Q46157366 | ||
| Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. | Q53134171 | ||
| Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. | Q53299557 | ||
| Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis | Q59587327 | ||
| Developments in early-stage NSCLC: advances in radiotherapy | Q59587387 | ||
| Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer | Q59587407 | ||
| Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer | Q59587541 | ||
| Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study | Q80587769 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| adaptive radiation therapy | Q180507 | ||
| P304 | page(s) | 630-637 | |
| P577 | publication date | 2015-05-13 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials | |
| P478 | volume | 16 |
| Q47428013 | "Even if I Don't Remember, I Feel Better". A Qualitative Study of Patients with Early-Stage Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy or Surgery |
| Q58706032 | 1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT |
| Q40271942 | 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. |
| Q92711228 | A Case Study of Exercise Adherence during Stereotactic Ablative Radiotherapy Treatment in a Previously Active Male with Metastatic Renal Cell Carcinoma |
| Q33786722 | A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer |
| Q38778226 | A Histologic Basis for the Efficacy of SBRT to the lung |
| Q90296646 | A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients |
| Q48256303 | A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q48312990 | A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC. |
| Q60308293 | A nomogram to predict prognosis in patients undergoing sublobar resection for stage IA non-small-cell lung cancer |
| Q35870182 | A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study |
| Q47877896 | A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors |
| Q41112332 | A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? |
| Q36651935 | A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II) |
| Q64279972 | A system-based intervention to reduce Black-White disparities in the treatment of early stage lung cancer: A pragmatic trial at five cancer centers |
| Q93347944 | A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q38689104 | AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future |
| Q40784236 | Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer |
| Q57498590 | Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up |
| Q96955067 | Added value of invasive needle techniques in mediastinal and hilar nodal staging of clinical N0-N1 non-small cell lung cancer after positron emission tomography |
| Q30993385 | Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy. |
| Q58804842 | Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma |
| Q98771156 | Adoption of Biologically Effective Dose of the Non-Target Lung Volume to Predict Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy With Variable Fractionations for Lung Cancer |
| Q64325572 | Advances in proton therapy in lung cancer |
| Q58804844 | Advances in radiation therapy for thoracic malignancies |
| Q33645619 | Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy |
| Q43251846 | Advances in targeting the transforming growth factor β1 signaling pathway in lung cancer radiotherapy |
| Q64282428 | Application of quality metrics to wedge resection for early stage non-small cell lung cancer demonstrates differences in overall survival |
| Q90751729 | Approach and assessment of automated stereotactic radiotherapy planning for early stage non-small-cell lung cancer |
| Q61804642 | Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer |
| Q40117156 | Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease |
| Q40608540 | Assessing the Need for Adjuvant Chemotherapy After Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Carcinoma |
| Q91910242 | Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial |
| Q50048666 | Automated ultrafast kilovoltage-megavoltage cone-beam CT for image guided radiotherapy of lung cancer: System description and real-time results |
| Q55045717 | Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes. |
| Q55036513 | Breaking the dose ceiling: proton therapy for locally advanced non-small cell lung cancer. |
| Q91632005 | CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer |
| Q93270752 | Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy |
| Q37663263 | Cardiotoxicity Following Cancer Treatment |
| Q92732573 | Casticin Induces DNA Damage and Affects DNA Repair Associated Protein Expression in Human Lung Cancer A549 Cells (Running Title: Casticin Induces DNA Damage in Lung Cancer Cells) |
| Q90353638 | Catheter-based alternative treatment for early-stage lung cancer with a high-risk for morbidity |
| Q91726224 | Changes in store for early-stage non-small cell lung cancer |
| Q88813122 | Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years |
| Q60300648 | Chemical composition, antioxidant and antitumor activities of sub-fractions of wild and cultivated Pleurotus ferulae ethanol extracts |
| Q99240991 | Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review |
| Q41432497 | Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges |
| Q90664798 | Circulating MicroRNAs as Potential Biomarkers for Lung Cancer |
| Q52591818 | Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. |
| Q38663392 | Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy |
| Q54983041 | Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors. |
| Q39321608 | Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma |
| Q59125770 | Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer |
| Q37691881 | Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer |
| Q57282048 | Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer |
| Q30834087 | Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system |
| Q60049439 | Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer |
| Q41559497 | Clinical results of accelerated hypofractionated radiotherapy for central-type small lung tumours |
| Q49286208 | Clinical results of proton beam therapy for elderly patients with non-small cell lung cancer |
| Q42820745 | Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy |
| Q47227265 | Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy. |
| Q58128516 | Collaborating to assess the role of stereotactic body radiation therapy in medically operable stage I non-small cell lung cancer |
| Q91700135 | Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy |
| Q55235684 | Combining radiation plus immunotherapy to improve systemic immune response. |
| Q58614800 | Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer |
| Q52587549 | Comparing Treatment Strategies for Stage I Small-cell lung Cancer. |
| Q90329536 | Comparing apples to oranges: short-term mortality after surgery versus stereotactic body radiotherapy for early-stage non-small cell lung cancer |
| Q37109928 | Comparing the clinical outcomes in stereotactic body radiotherapy for lung tumors between Ray-Tracing and Monte-Carlo algorithms |
| Q47446694 | Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. |
| Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
| Q91323191 | Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience |
| Q92407282 | Comparison of the Efficacy of Stereotactic Body Radiotherapy versus Surgical Treatment for Early-Stage Non-Small Cell Lung Cancer after Propensity Score Matching |
| Q57123979 | Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation |
| Q89726341 | Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients |
| Q42116312 | Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response |
| Q35996056 | Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer |
| Q38720384 | Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma |
| Q52763791 | Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study. |
| Q90095163 | Correlation of normal lung density changes with dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer |
| Q39249966 | Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: a Critical Review |
| Q49989260 | Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. |
| Q42907076 | Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens |
| Q58804492 | Cyberknife stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months |
| Q57155059 | Defining Optimal Comorbidity Measures for Patients with Early Stage Non-small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy (SBRT) |
| Q89521111 | Definitive radiation for early stage lung cancer: who is medically inoperable? |
| Q60908706 | Developments in Stereotactic Body Radiotherapy |
| Q92799118 | Diabetes mellitus is a predictive factor for radiation pneumonitis after thoracic radiotherapy in patients with lung cancer |
| Q64030451 | Die stereotaktische Strahlentherapie unterstützt die Immunantwort |
| Q38852610 | Differentially expressed protein-coding genes and long noncoding RNA in early-stage lung cancer |
| Q91786228 | Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC? |
| Q64075216 | Does aggressive management of solitary pulmonary nodules pay off? |
| Q99582784 | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis |
| Q39023519 | Dosimetric Improvements with a Novel Breast Stereotactic Radiotherapy Device for Delivery of Preoperative Partial-Breast Irradiation |
| Q93185154 | Dosimetric comparison of different algorithms in stereotactic body radiation therapy (SBRT) plan for non-small cell lung cancer (NSCLC) |
| Q55279174 | Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases. |
| Q40496623 | Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer |
| Q90087125 | Dosimetric impact of uncorrected systematic yaw rotation in VMAT for peripheral lung SABR |
| Q26751228 | Early detection of lung cancer |
| Q39049280 | Early lung cancer detection by low-dose CT screening: therapeutic implications |
| Q64969902 | Early stage lung cancer survival after wedge resection and stereotactic body radiation. |
| Q64081214 | Editorial on comparison between stereotactic body radiotherapy and surgery in early stage NCSLC by Scotti |
| Q55412836 | Editorial: Controversies in the Local Management of Lung Cancer. |
| Q47816339 | Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection |
| Q47752700 | Efficacy and safety of stereotactic body radiotherapy using CyberKnife in Stage I primary lung tumor |
| Q41241692 | Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer |
| Q61804647 | Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation |
| Q48010740 | Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients |
| Q37090175 | Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution |
| Q58760175 | Evaluation of delivered dose to a moving target by 4D dose reconstruction in gated volumetric modulated arc therapy |
| Q57175083 | Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham's (UK) Experience |
| Q89544503 | Exploratory analysis using machine learning to predict for chest wall pain in patients with stage I non-small-cell lung cancer treated with stereotactic body radiation therapy |
| Q89572724 | Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies |
| Q47868427 | Feasibility of using single photon counting X-ray for lung tumor position estimation based on 4D-CT. |
| Q90087120 | First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy |
| Q42668963 | Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation |
| Q55110451 | Flattening filter-free technique in volumetric modulated arc therapy for lung stereotactic body radiotherapy: A clinical comparison with the flattening filter technique. |
| Q38917758 | Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce |
| Q39041541 | From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? |
| Q55345592 | Guidelines for stereotactic body radiation therapy treatment of lung cancer highlight important research questions: what is the next step? |
| Q92424719 | Helping patients with lung cancer choose between surgery or stereotactic body radiotherapy: the importance of the patient experience |
| Q41678140 | High Dose Hypofractionated Proton Beam Therapy is a Safe and Feasible Treatment for Central Lung Cancer |
| Q91856165 | High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy |
| Q89354934 | Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy |
| Q92614906 | How rapid advances in imaging are defining the future of precision radiation oncology |
| Q64986638 | How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. |
| Q102067109 | Hypo-fractionation radiotherapy normalizes tumor vasculature in non-small cell lung cancer xenografts through the p-STAT3/HIF-1 alpha signaling pathway |
| Q90115551 | Hypofractionated 192Ir source stereotactic ablative brachytherapy with coplanar template assistance in the primary treatment of peripheral lung cancer |
| Q37601085 | Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer |
| Q33884923 | Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer |
| Q52716524 | Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience. |
| Q38763935 | Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? |
| Q37193638 | Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance) |
| Q33639144 | Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates |
| Q55398195 | Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. |
| Q30985297 | Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data |
| Q35996052 | Improving lung cancer outcomes by improving the quality of surgical care |
| Q64055804 | Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer |
| Q90218830 | Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy |
| Q40116176 | Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy. |
| Q88490364 | Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy |
| Q58131311 | Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy |
| Q31151418 | Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients |
| Q91734109 | Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report |
| Q50094335 | Invited Commentary. The Royalty of Evidence: The Randomized Control Trials |
| Q37583844 | Is it time for SABR to overtake surgery as the treatment of choice for stage I non-small cell lung cancer? |
| Q37384166 | Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy? |
| Q26749371 | Is surgery still the optimal treatment for stage I non-small cell lung cancer? |
| Q92159175 | Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? |
| Q36470566 | It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival |
| Q44422760 | Landmark study raises the bar for interventional oncology |
| Q38705115 | Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy |
| Q92356234 | Lobectomy in octogenarians: real world outcomes for robotic-assisted, video-assisted thoracoscopic, and open approaches |
| Q64997326 | Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. |
| Q49356980 | Lobectomy vs. radiotherapy for non-small-cell lung cancer patients |
| Q42348006 | Lobectomy: no port at all? |
| Q64233004 | Long non-coding RNA-NEF targets glucose transportation to inhibit the proliferation of non-small-cell lung cancer cells |
| Q55633259 | Long noncoding RNA UPAT promoted cell proliferation via increasing UHRF1 expression in non-small cell lung cancer. |
| Q64901117 | Long non‑coding RNA NORAD promotes cell proliferation and glycolysis in non‑small cell lung cancer by acting as a sponge for miR‑136‑5p. |
| Q37077160 | Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis |
| Q50862063 | Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. |
| Q38990272 | Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer |
| Q37491637 | Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). |
| Q55392268 | Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey. |
| Q52613276 | Lung density change after SABR: A comparative study between tri-Co-60 magnetic resonance-guided system and linear accelerator. |
| Q89635257 | Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent? |
| Q89422484 | Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature |
| Q91792791 | Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial |
| Q55711165 | Minimally invasive surgery is best treatment for early lung cancer. |
| Q49896456 | Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma. |
| Q60922994 | Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients |
| Q36382553 | Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients |
| Q40542033 | Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors |
| Q40656245 | Multicenter prospective study of sublobar resection for c-stage I non-small cell lung cancer patients unable to undergo lobectomy (KLSG-0801): complete republication |
| Q38930381 | Multidisciplinary Care |
| Q39369140 | Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. |
| Q36299306 | Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer |
| Q54976438 | Non-Small-Cell Lung Cancer: Feasibility of Intratumoral Radiofrequency Hyperthermia-enhanced Herpes Simplex Virus Thymidine Kinase Gene Therapy. |
| Q88867981 | Non-coplanar VMAT combined with non-uniform dose prescription markedly reduces lung dose in breath-hold lung SBRT |
| Q39108884 | Noteworthy Literature Published in 2016 for Thoracic Surgery |
| Q26775388 | Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies |
| Q64112551 | OTU deubiquitinase 4 is silenced and radiosensitizes non-small cell lung cancer cells via inhibiting DNA repair |
| Q50651784 | Opinions of lung cancer clinicians on shared decision making in early-stage non-small-cell lung cancer. |
| Q89622218 | Optimal management of pulmonary ground-glass opacity nodules |
| Q61804648 | Optimizing immobilization, margins, and imaging for lung stereotactic body radiation therapy |
| Q64276234 | Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis |
| Q54974804 | Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study. |
| Q55073985 | Particle therapy in non-small cell lung cancer. |
| Q47361297 | Patient-clinician communication among patients with stage I lung cancer |
| Q64267035 | Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer |
| Q48202266 | Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). |
| Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
| Q38676392 | Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy |
| Q47269792 | Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). |
| Q89450297 | Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients |
| Q41067520 | Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy |
| Q41092061 | Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy |
| Q37739358 | Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors |
| Q60907498 | Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis |
| Q90257623 | Premature Termination of a Randomized Controlled Trial on Image-Guided Stereotactic Body Radiotherapy of Metastatic Spinal Cord Compression |
| Q94465235 | Pretreatment Factors Influencing Radiation Pneumonitis after Stereotactic Body Radiation Therapy in the Treatment of Lung Cancer |
| Q38925620 | Prognositc significance of SUVmax on pretreatment 18 F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis |
| Q37152914 | Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy |
| Q88089866 | Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer |
| Q60938857 | Promising Clinical Outcome With Long Term Follow-Up After Body Gamma Knife Stereotactic Radiosurgery for Patients With Early Stage Non-small Cell Lung Cancer |
| Q42330755 | Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy |
| Q36241814 | Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q55208073 | Proton therapy for early-stage non-small cell lung cancer (NSCLC). |
| Q91926008 | Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial |
| Q38849150 | Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? |
| Q99582912 | Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience |
| Q33728897 | Radiation Oncology Physician Practice in the Modern Era: A Statewide Analysis of Medicare Reimbursement |
| Q55038620 | Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't! |
| Q33593244 | Radiation therapy for hepatobiliary malignancies |
| Q36454693 | Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells |
| Q47095312 | Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). |
| Q42109226 | Radiotherapy for Oligometastatic Lung Cancer |
| Q39385461 | Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach |
| Q94592974 | Radiotherapy in Lung Cancer: Current and Future Role |
| Q38870545 | Radiotherapy in patients with HIV: current issues and review of the literature. |
| Q53688649 | Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. |
| Q57875955 | Radiothérapie en conditions stéréotaxiques des patients inopérables |
| Q39181674 | Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. |
| Q99239657 | Reactive Oxygen Species Modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study |
| Q39223364 | Real-time 4D dose reconstruction for tracked dynamic MLC deliveries for lung SBRT. |
| Q46034873 | Real-time tomosynthesis for radiation therapy guidance. |
| Q26747020 | Recent Advances in Bronchoscopic Treatment of Peripheral Lung Cancers |
| Q47105316 | Recent advances in the management of non-small cell lung cancer |
| Q47986975 | Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe |
| Q36301196 | Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol |
| Q40455887 | Reducing scan angle using adaptive prior knowledge for a limited-angle intrafraction verification (LIVE) system for conformal arc radiotherapy. |
| Q52450428 | Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques. |
| Q52878867 | Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation. |
| Q36938199 | Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma. |
| Q64946137 | Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT. |
| Q55119541 | Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. |
| Q39496906 | Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer |
| Q42590974 | Risk calculators are useful but.... |
| Q48233447 | Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. |
| Q87322426 | SABR in early operable lung cancer: time for evidence |
| Q86150669 | SABR vs surgery for NSCLC in the media |
| Q38813253 | SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer? |
| Q93080685 | SABR-COMET: harbinger of a new cancer treatment paradigm |
| Q98157769 | SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges |
| Q39135612 | SBRT for centrally localized NSCLC - What is too central? |
| Q42384628 | SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation |
| Q38863092 | Safety and feasibility of prolonged bronchoscopy involving diagnosis of lung cancer, systematic nodal staging, and fiducial marker placement in a high-risk population |
| Q90697953 | Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients |
| Q39265624 | Salvage surgery after high-dose radiotherapy |
| Q63367919 | Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review |
| Q47428325 | Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer |
| Q42359042 | Shared decision making in the treatment of stage I non small cell lung cancer-a choice which should equally involve both sides |
| Q38994894 | Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). |
| Q57805631 | Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer |
| Q55251778 | Similar results of robotic and uniportal videothoracoscopic surgery for lung cancer treatment. |
| Q38871523 | Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies |
| Q37013991 | Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance |
| Q42384638 | Stage I lung cancer-to operate or to radiate? that is the question |
| Q40308740 | Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer |
| Q52886428 | Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer. |
| Q39342656 | Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer |
| Q91996939 | Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non-Small Cell Lung Cancer |
| Q57764566 | Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study |
| Q93378567 | Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers |
| Q49310050 | Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. |
| Q42558770 | Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer |
| Q42362383 | Stereotactic ablative body radiation therapy or surgery for operable early non-small cell lung cancer patients: bound hand and foot to evidence. |
| Q41112569 | Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard |
| Q38828265 | Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy? |
| Q35783598 | Stereotactic ablative radiotherapy and surgery: two gold standards for early-stage non-small cell lung cancer? |
| Q92127930 | Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer |
| Q38549543 | Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution |
| Q89507738 | Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer |
| Q50096367 | Stereotactic ablative radiotherapy versus lobectomy for stage I non-small cell lung cancer: A systematic review |
| Q91631990 | Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial |
| Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
| Q55282076 | Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives. |
| Q64081395 | Stereotactic body radiation therapy and surgery for early lung cancer "two sides of the same coin" |
| Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
| Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
| Q91875040 | Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer |
| Q64228173 | Stereotactic body radiation therapy for pulmonary large cell neuroendocrine carcinoma: a case report |
| Q40073828 | Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients |
| Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
| Q64928708 | Stereotactic body radiation therapy versus metastasectomy for oligometastases. |
| Q30992150 | Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis |
| Q64922876 | Stereotactic body radiation therapy versus surgery for early stage non-small cell lung cancer: clearing a path through an evolving treatment landscape. |
| Q55062398 | Stereotactic body radiation therapy vs. surgery in early-stage non-small cell lung cancer: lessons learned, current recommendations, future directions. |
| Q64917835 | Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study. |
| Q90329602 | Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality |
| Q38935913 | Stereotactic body radiotherapy for oligoprogressive cancer |
| Q90329595 | Stereotactic body radiotherapy for operable, early stage non-small cell lung cancer-let's all take a deep breath |
| Q38783194 | Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions |
| Q41273661 | Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study. |
| Q26781806 | Stereotactic body radiotherapy in lung cancer: an update |
| Q90701467 | Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity |
| Q33813299 | Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis |
| Q39769743 | Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma: comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A). |
| Q28076058 | Stereotactic body radiotherapy: current strategies and future development |
| Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
| Q48183175 | Stereotactic radiotherapy for primary renal cell carcinoma: time for larger-scale prospective studies |
| Q87273860 | Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer |
| Q59587237 | Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer – Authors' reply |
| Q39123715 | Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice |
| Q47159062 | Summary of the lecture given on June 1, 2017 on the occasion of the Jacob I. Fabrikant Award ceremony |
| Q38732479 | Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy |
| Q57864954 | Surgery SBRT in retrospective analyses: confounding by operability is the elephant in the room |
| Q90087984 | Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses |
| Q47106372 | Surgery compared to stereotactic body radiation therapy for early-stage non-small cell lung cancer: better, equivalent or worse? |
| Q47781280 | Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis. |
| Q42354883 | Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise |
| Q55012865 | Surgery versus SABR for resectable non-small-cell lung cancer |
| Q85846446 | Surgery versus SABR for resectable non-small-cell lung cancer |
| Q95419806 | Surgery versus SABR for resectable non-small-cell lung cancer |
| Q95419835 | Surgery versus SABR for resectable non-small-cell lung cancer |
| Q59587263 | Surgery versus SABR for resectable non-small-cell lung cancer – Authors' reply |
| Q52836419 | Surgery versus SABR for resectable non-small-cell lung cancer. |
| Q26748296 | Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more |
| Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
| Q58764285 | Surgical Resection Versus Stereotactic Body Radiation Therapy for Stage I NSCLC: Can Randomized Trials Provide the Solution? |
| Q53101096 | Survival Outcome after Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer: A Meta-Analysis. |
| Q90138365 | Survival of Primary SBRT Compared to Surgery for Operable Stage I/II Non-Small Cell Lung Cancer |
| Q47108053 | Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience |
| Q91737684 | Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway |
| Q92725532 | Technical Assessment of an Automated Treatment Planning on Dose Escalation of Pancreas Stereotactic Body Radiotherapy |
| Q64967557 | The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. |
| Q38792207 | The IR Evolution in Oncology: Tools, Treatments, and Guidelines |
| Q36176801 | The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development |
| Q89520902 | The PEMBRO-RT phase II randomized trial and the evolution of therapy for metastatic non-small cell lung cancer: a historical perspective |
| Q92605873 | The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer |
| Q37497743 | The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage |
| Q61804644 | The current and future faces of stereotactic body radiation therapy for thoracic malignancies |
| Q91800465 | The current state of randomized clinical trial evidence for prostate brachytherapy |
| Q96138240 | The debate for thermal ablation of colorectal cancer pulmonary metastases is heating up |
| Q38967475 | The development of stereotactic body radiotherapy in the past decade: a global perspective |
| Q41954362 | The evolving evidence for the efficacy and safety of charged particle therapy for hepatocellular carcinoma-a commentary |
| Q90175125 | The evolving role of radiotherapy in non-small cell lung cancer |
| Q38625125 | The evolving role of radiotherapy in treatment of oligometastatic NSCLC. |
| Q38751141 | The future of image-guided radiotherapy will be MR guided |
| Q50138849 | The great debate flashes: Surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer |
| Q61804643 | The optimal treatment approaches for stage I small cell lung cancer |
| Q38928692 | The radiobiological targets of SBRT: tumor cells or endothelial cells? |
| Q30248748 | The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. |
| Q64080769 | The role of small or single-institution prospective studies in thoracic research |
| Q64120986 | The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy |
| Q64111832 | Three discipline collaborative radiation therapy (3 DCRT ) special debate: I would treat all early‐stage NSCLC patients with SBRT |
| Q91600204 | Timeliness of Lung Cancer Diagnosis and Treatment |
| Q38780270 | Treatment Burden of Medicare Beneficiaries With Stage I Non-Small-Cell Lung Cancer |
| Q64118469 | Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy |
| Q50863889 | Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours. |
| Q47164549 | Treatment recommendations by clinicians in stage I non-small cell lung cancer: better work-up leads to less discussion |
| Q50044375 | Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making |
| Q92645649 | Treatment strategy and decision-making for elderly surgical candidates with early lung cancer |
| Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
| Q47648038 | Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013. |
| Q38962875 | Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what? |
| Q55012601 | Two lives |
| Q47123759 | Under-treatment of small cell lung cancer: the case for surgical resection |
| Q64355411 | Understanding patients' values and preferences regarding early stage lung cancer treatment decision making |
| Q38859683 | Undetected lymph node metastases in presumed early stage NSCLC SABR patients |
| Q47141436 | Unless I see, I will not believe. |
| Q41115829 | Update in Lung Cancer 2015. |
| Q92356100 | Verification of meta-analysis and propensity-matched analysis comparing stereotactic body radiation therapy versus surgery for early stage lung cancer |
| Q89067458 | Virtual Bronchoscopy-Guided Treatment Planning to Map and Mitigate Radiation-Induced Airway Injury in Lung SAbR |
| Q42318777 | What if a tumor is significantly enlarged just before stereotactic body radiation therapy? A case report and review of the literature |
| Q42340577 | What is the role of stereotactic ablative radiotherapy in the management of surgically resectable and operable stage I non-small cell lung cancer? |
| Q92467682 | Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate |
| Q52936448 | Young at Heart: Is That Good Enough for Computed Tomography Screening? |
| Q53080274 | [Advances in Surgical Treatment of Early Stage Non-small Cell Lung Cancer]. |
| Q88208674 | [Different mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer] |
| Q57641071 | [Local treatment of solitary intrapulmonary, malignant nodules] |
| Q89921619 | [Minimally Invasive Therapies For Early Stage Non-Small Cell Lung Cancer] |
| Q53423125 | [Stereotactic Ablative Radiotherapy for Operable Stage I Non-small Cell Lung Cancer in Clinical Practice: How Long Way to Go?]. |
Search more.